Showing posts with label Obesity. Show all posts
Showing posts with label Obesity. Show all posts

11 February 2010

Menopause



Menopause
Division of Urogynecology and Reconstructive Pelvic Surgery
Department of OB/GYN

Epidemiology
* Average age is 51.4 years
* 95% confidence interval of Bell Curve gives a range of 45-55 years. Less than 2% occur before age 40.
* Factors associated with early menopause
o Cigarette smoking (1.5 yrs earlier)
o History of short intermenstrual interval
o Family history
o Chemo / Radiation / Genetic factors
* Unrelated to number of prior ovulations, pregnancies, use of OCPs, height, weight, age at menarche, race, class or education

Elderly Population
* In 2000, life expectancy:
o Women 79.7 years
o Men 72.9 years
* Once you reach 65:
o Women expect to live until 84.3 years old
o Men expect to live until 80.5 years old
* Therefore, more than 1/4 of a woman’s life is spent in menopause

Peri-menopause
* Peri-menopause
o Transitional period
+ Hallmark is menstrual irregularities
# Shortened cycle length
# Skipped cycles
# 10% of women will have abrupt cessation of menses
+ Median length of 4-5 years
o Median age of onset is 47.5 years

Physiology
General feature is depletion of follicles with loss of granulosa and thecal cell function
* 6-7 million oocytes at 20 weeks fetal age
* 1 million oocytes at birth drop to 400,000 at puberty
* 300-400 ovulatory events over lifetime
* Accelerated follicular loss 2-8 yrs before menopause

Physiology
* Granulosa cells produce less inhibin, which provides negative feedback for FSH secretion by the pituitary gland.
* Increase in FSH levels
* After menopause, LH levels are also elevated.
* Would you check a FSH or LH level to diagnose menopause?

Symptoms
* Menstrual irregularities is the primary reason women seek medical attention
* Cycles shorten as increased FSH triggers early ovulation
* Skipped cycles due to anovulation
* Long periods of anovulation can lead to excessive estrogen states and irregular, unexpected menses
* Do you think the perimenopausal women can get pregnant?
o YES
o Guinness World Record = 57 yrs & 120 days
o So, remember to recommend contraception. Low does oral contraceptives may be used in women without contraindications (i.e. smoking).
* Hot Flushes
o Subjective feeling of intense heat followed by skin flushing and diaphoresis.
o Sudden dilation of peripheral vasculature secondary to abrupt estrogen withdrawal. Skin temperature increases and core temperature drops.
o Usually, occurs for a few seconds to minutes.
o Duration is about 1-2 years. 25% for > 5 years.
* Genitourinary atrophy
o A variety of symptoms
o Atrophic vaginitis, urethritis, recurrent UTIs, dyspareunia
o Pelvic organ prolapse is NOT caused by estrogen deficiency
* Urinary Incontinence
o Atrophy of estrogen-dependant tissues such as the urethra may contribute to existing causes for urinary incontinence
o Typically addressed with local application of estrogen cream
* Sexual Disturbances
o Decreased interest in sexual activity
+ May be related to decreased testosterone levels
+ May be related to psychosocial stressors
o Anatomic changes secondary to estrogen deficiency
+ Atrophy of vaginal mucosa and lower urethra
+ Thinning of vaginal mucosa with decreased lubrication and elasticity, leading to dyspareunia
* Sleep Disturbances
o Estrogen appears related to producing restful, deep-stage sleep
o Hot flushes more common at night
+ Wakening or disruption of deep-stage sleep
+ Contributes to feeling of overall fatigue
* Mood Swings / Irritability / Depression
o NOT associated with menopausal hormone changes alone
o Stage of life associated with multiple changes (e.g., children leaving home, parents aging, retirement)
o Hot flushes and fatigue can lead to emotional lability
* Cognitive Function
o Some types of memory and brain function may be influenced by estrogen
o Some evidence suggests that Alzheimer’s disease is less frequent in estrogen users and the effect was greater with increasing dose and duration of use.

Adverse Health Effects
* Cardiovascular Disease
o Leading cause of death in US women (f/b malignancies, cerebrovascular disease and MVAs)
o Death rate for CV disease is 3X the rate for breast cancer and lung cancer.
o Changes in lipid profile in menopause
+ Increased LDL
+ Decreased HDL
+ ? Decrease in triglycerides
* Osteoporosis
o Spinal bone density peaks at 20 years, while cortical bone density peaks in late 20s
o Rate of loss of 0.5%/year prior to age 40, then anywhere from 2-9%/year for first 10-15 years after menopause
o Primary loss is trabecular bone, leading to compression fractures, loss of height, kyphosis
o Osteopenia = BMD between -1 and -2.5 SD of a young, white adult woman.
o Osteoporosis = BMD -2.5 or greater SD
o 25-50% of women will have spinal compression fractures by age 70
o 20% of Caucasian women age 80 will have hip fractures, with 15-20% mortality.
o Annual incidence is 1.3% after age 65
o High risk:
+ Caucasian, Asian
+ Thin, inactive, smokers
+ High caffeine/alcohol intake, low dietary calcium, high dietary protein and phosphates
+ H/o oligomenorrhea, excessive exercise, eating disorder
+ Medical conditions – hyperthyroid, cancer, myeloproliferative disorders
o Low Risk:
+ African American
+ Obese, active
o Protection:
+ Ca supplements (1200mg, 1500mg)
+ Weight-bearing exercise
+ HRT: estrogen increases
# Intestinal calcium absorption
# Renal conservation of calcium
# Increases 1,25-dihydroxyvitamin D (active form)
+ Vitamin D (400-800IU)

Hormone Replacement
* Types of hormone replacement
o Estrogen alone (for women without a uterus)
o Estrogen and progesterone
+ Sequential
+ Continuous
o Local estrogen
o SERM’s (Selective Estrogen Receptor Modulators)

HRT - Advantages
1. Relief of vasomotor symptoms
+ HRT is effective in reduces the number of hot flashes
+ 6-8 weeks to see maximal effect
+ Combination HRT (0.625mg estrogen/2.5mg MPA)
+ What about lower doses of HRT?
# For combination HRT, all doses resulted in similar relief of symptoms
# For estrogen alone, most relief with higher doses
2. Vaginal atrophy

# Menopause thins the vaginal epithelium and increases the vaginal pH (> 6.0).
# Estrogen decreases the vaginal pH, thickens the vaginal epithelium and reverses vaginal atrophy.
# Less atrophic changes with higher doses of HRT
3. Bone protection

+ Reduction of bone loss
+ Prevents OP-related hip fractures
+ Protects the spine and the small bones
+ WHI: 5 fewer hip fractures per 10,000 person-yrs
4. Colon cancer

o Some observational studies have suggested a reduced risk.
o WHI: 6 fewer cases / 10,000 person-yrs
1. Endometrial cancer
+ 8-10 fold increased risk with unopposed estrogen.
+ PEPI: unopposed estrogen x 3 yrs = 24% with atypical hyperplasia (vs 1% women on placebo)
+ Risk is increased with:
# Increased duration and dose
# Continuous versus cyclic therapy
# Absence of a progestin
2. Breast cancer

o Meta-analysis of 51 case-controlled & cohort studies showed no increased risk with short-term use.
o After 5 years of use, risk increased by 35%.
o WHI: 8 more invasive cases / 10,000 person-yrs
o Women diagnosed with breast cancer while using HRT have been shown to have better survival

HRT - Disadvantages

3. Thromboembolic disease

o Increases risk for DVT 2 – 3.5 fold
o Strokes: 8 more / 10,000 person-yrs
o PEs: 8 more / 10,000 person-yrs

HRT - Disadvantages

4. Cardiovascular disease:

o Traditionally, HRT was thought to provide protection against coronary heart disease (CHD)
o Observational studies found lower rates of CHD in postmenopausal women on HRT.
o The consensus was that CHD was about 35-50% lower in women using HRT.
o Many studies showed that HRT improved lipid profiles.

HRT - Disadvantages

4. Cardiovascular disease:

o What about secondary prevention? i.e. women who have a h/o coronary heart disease, does HRT help?
o Heart and Estrogen/Progestin Replacement Study (HERS) was a RCT, double-blinded study of 2,763 PM women with intact uteri and a h/o CHD
o 52% higher rate of major coronary events in the 1st year
o Then there was a reduction in the risk with longer use – i.e. 33% lower risk in the 4th and 5th years
o What about primary prevention? i.e. in healthy women, does HRT prevent CHD?
o Women’s Health Initiative (WHI)
o RCT of 16,608 postmenopausal women aged 50-79 years old with an intact uterus
o 40 different US centers
o Combination HRT – 0.625mg CEE and MPA 2.5mg vs placebo

Cardiovascular disease (WHI):
o 7 more CHD events
o 8 more strokes
o 8 more PEs
o 8 more invasive cancers
o Study stopped after 5.2 yrs (planned 8.5yrs) because of cases of breast cancer

SERMs
* Selective estrogen receptor modulators
* Work as agonists and antagonists depending on the tissue
* Raloxifene and tamoxifen

Estrogen Raloxifene Tamoxifen

Prevent OP
Risk Breast
Cancer
Hot Flashes
Endometrial
Cancer
Venous
Thrombosis
SERMs
* Overall, SERMs can help to prevent OP and breast cancer
* However, they aggravate hot flashes, the most common indication for estrogen therapy.
* Also, tamoxifen stimulates the endometrium.

Alternative Medicine
* Limited studies with relatively short duration of therapy and follow-up.
* Soy and isoflavones may be helpful in the short-term (< 2 yrs) for vasomotor sx and may protect against osteoporosis.
* 35-75mg qd isoflavones / day
* Black cohosh may be helpful in the short-term (< 6 mos) for vasomotor symptoms.

Summary
* Health Risks
o Osteoporosis
o Lipid abnormalities
o Cardiovascular disease
o Cancer
* Menopause is the natural course aging of the female reproductive system, driven by loss of oocytes
* Symptoms of menopause include:
o Menstrual irregularities
o Hot flushes
o Sleep disturbances
o Mood changes
o Sexual disturbances
o Urinary incontinence
o Cognitive function
o Hair growth

Hormone Replacement
Benefits
Detriments

* Vasomotor sx
* Vaginal atrophy
* Osteoporosis
* Colon cancer
* Endometrial ca
* Breast ca
* VTE
* CHD

Abnormal Bleeding
* A 44-year old woman presents for evaluation of abnormal menstrual bleeding. Her periods have been regular in the past but for the last 6 months she has had a period every 35-56 days, lasting 7-9 days. The bleeding is heavier than usual and she feels tired all the time. She has gained 15 lbs over the last 2 years, which she believes is due to lack of exercise and increased eating/sleeping. She complains that her skin is dry. Exam is unremarkable. What would your recommend next?
o Check pregnancy test
o Discuss exercise / eating patterns
o Check TSH, PRL
o Consider endometrial biopsy
o Expectant management versus hormonal management

Health Maintenance
* 58 year old postmenopausal woman referred to you by a friend. She has no known medical problems and is on no medications. Her social history is remarkable for an 80-pack/year history of tobacco use. Her physical exam is unremarkable. What are the important health maintenance aspects of the exam to focus on?
o Blood pressure
o Pelvic exam
o Breast exam / mammography
o Fecal occult blood
o Smoking cessation
o Flu shot
o Osteoporosis

Abnormal Bleeding
* A 47 year old woman, G2P2, presents with menstrual cycles varying in length from 20 to 40 days. Until 9 months ago she had regular 28 day cycles. She reports frequent hot flushes. She recently resumed sexual activity and uses no contraception, but she does not desire pregnancy. She does not smoke and has no other medical problems. Her physical exam is unremarkable. What are her options for cycle control?
o Low dose combination oral contraceptive
o Continuous low dose estrogen and progestin menopause regimen
o Cyclic progestin therapy for 12 days a month
o Continuous low dose estrogen (0.625mg conj EE)
o Estradiol vaginal ring

Osteoporosis

* A menopausal patient with osteoporosis has been reading information on the Internet about different treatment modalities for osteoporosis. She wishes to know more about what therapies are actually available and how they work?
o Estrogen: Reduces osteoclast activity
o SERMs: Reduces osteoclast activity
o Bisphosphonates: Reduces osteoclast activity
+ Take on empty stomach, first thing in AM with 8oz water and no food for 30 minutes
+ Take sitting up due to esophagitis risk
+ Calcium supplementation within 4 hours
o Calcium / Vitamin D supplements

Menopause.ppt

Read more...

11 January 2010

Male Obesity and Semen Analysis Parameters



Male Obesity and Semen Analysis Parameters
By:Joseph Petty, MD
Samuel Prien, PhD
Amantia Kennedy, MSIV
Sami Jabara, MD

Background: Obesity

* Obesity is a growing problem.
* The Behavioral Risk Factor Surveillance System, in conjunction with the CDC, conducted a national survey and found that in 2000, the prevalence of obesity (BMI >30 kg/m2) was 19.8%, a 61% increase since 1991.
* Obesity affects female and male fertility.
* In a study comparing IVF success rates and female obesity, it was shown that a 0.1 unit increase in waist-hip ratio led to a 30% decrease in probability of conception per cycle 2.
* In couples complaining of infertility, male factor plays a role in up to 40% of cases.

Background: Semen Parameters
* What parameters best predict fertility?
* National Cooperative Reproductive Medicine Network: 765 infertile couples (no conception after 12 months), and 696 fertile couples
* greatest discriminatory power was in the percentage of sperm with normal morphologic features.

Hypothesis
* Since there is an observed correlation between obesity and male factor infertility, our hypothesis is that an increased BMI is associated with higher rate of abnormal semen parameters, especially sperm morphology.

Recent Studies
* Danish study by Jensen et al. enrolled 1,558 young men (mean 19 years old) when they presented for their compulsory physical exam as part of their country’s military drafting system.
* The authors showed decreased sperm counts and concentration (39 million/mL vs. 46million/mL) in those with an elevated BMI (>25kg/m2). They did not, however, observe a difference in morphology.
* Hormonal differences
* Kort et al. looked at semen analysis results in 520 men
* grouped according to their BMI, and measured the average normal-motile-sperm count (NMS = volume x concentration x %motility x %morphology)
* Kort concluded that men with high BMI values (>25) present with few normal-motile sperm cells
* Hammoud et al., showed a increased incidence of oligospermia and increased BMI and also showed decreased levels of progressively motile sperm
* Considered each parameter separately.

Sexual function
* Agricultural study: The association between BMI and infertility was similar for older and younger men, disproving the theory that erectile dysfunction in older men is a significant factor.
* Hammoud et al., though primarily concerned with hormones, looked at erectile dysfunction directly and showed that there was no correlation with increases in BMI
* Nguyen et al., effect of BMI is essentially unchanged regardless of coital frequency, suggesting that decreased libido in overweight men is not a significant factor

Hormonal Profile
* Danish study, observed decreased FHS and inhibin B levels in the obese.
* Pauli et al., observed with increases in BMI a decreased total T, decreased SHBG, increased estrogen and decreased FSH and inhibin B.
* Inhibin B, cited for its usefulness as a novel marker for spermatogenesis and its role in pituitary gonadotropin regulation.
* Pauli: no correlation of BMI or skinfold thickness with semen analysis parameters, though it was observed that men with proven paternity versus those without had lower BMI.

Interventions: Gastric Bypass
* One case series of 6 male patients after bariatric surgery showed secondary azoospermia with complete spermatogenic arrest.
* none of the subjects had a semen analysis before the bariatric surgery, but all had fathered a pregnancy previously
* malabsorption of nutrients
* Hammoud et al., part of Utah Obesity Study
* effect of the gastric bypass surgery on sex steroids and sexual function
* Cohort of 64 severely obese men
* Along with a significant decrease in BMI, they found decreased levels of estradiol, and increases in total and free testosterone along with a reported improvement in quality of sexual function.
* Semen analysis parameters were not considered in this study

Study Design
* Retrospective chart review for all couples and individual patients presenting for an infertility consultation and evaluation at the Texas Tech Physicians Center for Fertility and Reproductive Surgery from September 2005 through January 2008.
* Intake questionnaire: demographic, medical, surgical and fertility history.

Questionnaire
* Previous pregnancies fathered: current or previous partner
* Psychiatric disorders included any degree of depression, bipolar disorder or any other psychiatric disorder requiring medical therapy.
* Tobacco and alcohol users: whether they admitted to light, moderate, or heavy use, patient underreporting.
* Chemical exposures: contact with pesticides, herbicides, and heavy metals.
* Sexual dysfunction: mainly erectile dysfunction and decreased libido.
* Genitourinary anomalies: hypospadias, varicocele, genitourinary surgery, testicular torsion or inguinal hernia or trauma
* Other medical problems included mainly diabetes, hypertension, thyroid disease, autoimmune disease, and cancer.
* Patients grouped according to their BMI as normal (20-24 kg/m2, N = 24), overweight (25-30 kg/m2, N = 43), or obese (>30 kg/m2, N = 45), as standardized by the World Health Organization
* Semen analysis parameters: morphology, volume, concentration, percent motility, and presence of absence of agglutination, in accordance with World Health Organization (WHO) guidelines
* SPSS statistical software was used to run analysis of variance (ANOVA) and post-hoc Tukey HSD tests between the groups. A p-value <0.05 was considered statistically significant.

Exclusion Criteria
* questionnaire was missing or if they had an otherwise incomplete chart.
* missing vital statistics (i.e. height and weight),
* 235 total charts reviewed,
o 60 no semen analysis or outside lab.
o 63 patients had either missing vital statistics or a missing questionnaire
o This left a total of 112 patients with valid data to be considered.


Results
* The BMI groups were statistically similar as far as demographic characteristics and confounding variables
* There was no statistically significant difference between the semen parameters of all three BMI groups.
* slight trend towards a decreasing sperm concentration with increases in BMI

Conclusion
* In this study, overweight and obese men did not have an increased rate of teratozoospermia, asthenospermia, or oligospermia.

Discussion
* Inconsistencies
* Small sample size
* Kort and data interpretation
* Change the normal hormonal milieu, addressed by Jensen study.
* Sertoli cell function, increased aromatase, role of leptin
* Aggerholm study: altered hormones not correlated with semen abnormalities in overweight men (25.1-30.0 kg/m2), slightly decreased sperm concentration in overweight but not in obese


Future Studies
* What affects morphology specifically?
o Hormones
o Result of secondary disease, i.e.. Diabetes
o Genetic mutations
o Weight loss surgery and other interventions
* Overall, there is no doubt that increases in BMI have a detrimental effect on male fertility, but a satisfactory explanation of the mechanism for this phenomenon has yet to be given.

References
Male Obesity and Semen Analysis Parameters

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP